Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-13
2006-06-13
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C435S320100, C435S069100
Reexamination Certificate
active
07060687
ABSTRACT:
The invention relates to transformed bacteria of the genusLactobacillusorStreptococcus,the bacteria having a DNA molecule that includes (1) a nucleotide sequence that encodes a protein allergen and (2) a promoter operably linked to the nucleotide sequence.
REFERENCES:
patent: 5032399 (1991-07-01), Gorbach et al.
patent: 5494664 (1996-02-01), Brassart et al.
patent: 5556953 (1996-09-01), Zhang et al.
patent: 5698204 (1997-12-01), Rogers et al.
patent: 5709857 (1998-01-01), Morelli et al.
patent: 5776761 (1998-07-01), Rogers et al.
patent: 5814345 (1998-09-01), Beck et al.
patent: 5869333 (1999-02-01), Singh et al.
patent: 5888799 (1999-03-01), Curtiss, III
patent: 5939283 (1999-08-01), Morgenstern et al.
patent: 5951984 (1999-09-01), Kaneko et al.
patent: 5958891 (1999-09-01), Hsu et al.
patent: 6048962 (2000-04-01), Gefter et al.
patent: 6077517 (2000-06-01), Thomas et al.
patent: 6100388 (2000-08-01), Casas et al.
patent: 6110898 (2000-08-01), Malone et al.
patent: 6180368 (2001-01-01), Singh et al.
patent: 6413738 (2002-07-01), Thomas et al.
patent: 6737521 (2004-05-01), Fischetti et al.
patent: 1387442 (2002-12-01), None
patent: 8700890 (1988-11-01), None
patent: WO 92/00756 (1992-01-01), None
patent: WO 95/35389 (1995-12-01), None
patent: WO 97/14802 (1997-04-01), None
patent: WO 00/35484 (2000-06-01), None
patent: WO 00/52154 (2000-09-01), None
patent: WO 01/34186 (2001-05-01), None
patent: WO 01/66136 (2001-09-01), None
Kailasapathy et al. Survival and therapeutic potential of probiotic organisms with reference toLacrobacillus acidophilusand Bifidobacterium spp. pp. 80-88 1999.
Janeway Jr., Immunobiology, 1999.
Pouwels et al, Intl J Food Microbial 1998:41:155-67.
Janeway Jr., Immunobiology, 2001, §14-25.
Jahn-Schmid et al, Immunotechnol 1996;2: 103-13.
Aas et al., “Standardization of Allergen Extracts with Appropriate Methods,”Allergy 33:130-137(1978).
Goldin et al., “Health benefits of probiotics,”Br. Jour. Nut.80:S203-S207 (1998).
Hakkaart et al, “Expression of the house dust mite allergen Der p 2 in the baker's yeastSaccharomyces cerevisiae,” Blackwell Science Ltd.28:45-52 (1998).
Hsu et al., “Inhibition of specific IgE response in vivo by allergen-gen transfer,”International Immunology, 8:1405-1411 (1996).
Kailasapathy et al., “Survival and therapeutic potential of probiotic organisms with reference toLactobacillus acidophilusandBifidobacteriumspp.,”J. Immunol. Cell Biol.78:80-88 (2000).
Lin et al., “Characterization of Der p V allergen, cDNA analysis, and IgE-mediated reactivity to the recombinant protein,”J. Allergy Clin. Immunol.94:6:989-996 (1994).
Pouwels et al., “The potential ofLactobacillusas a carrier for oral immunization: Development and preliminary characterization of vector systems for targeted delivery of antigens,”Jour. of Biotechnology44:183-192 (1996).
Salminen et al. “Functional food science and gastrointestinal physiology and function,”Br. J. Neutr.80:S147-S171 (1998).
Fischetti, et al., “Expression of foreign proteins on Gram-positive commensal bacteria for mucosal vaccine delivery,”Current Opinion in Biotechnology4, 603-610 (1993).
Hoyne, et al., “Characterization of T-cell responses to the house dust mite allergen Der p II in mice. Evidence for major and cryptic epitopes,”Immunology78 65-73 (1993).
Hoyne et al., Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerancein vivo International Immunology8:3, 335-342 (1996).
Hoyne, et al., “Inhibition of T Cell and Antibody Responses to House Dust Mite Allergen by Inhalation of the Dominant T Cell Epitope in Naïve and Sensitized Mice,”J. Exp. Med178, 1783-1788 (1993).
Hsu, et al., Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsivenessin vivoby genetic immunization,Nature Medicine2:5 (1996).
Kato, et al., “Suppressive Effects of the Oral Administration ofLactobacillus caselon Type II Collagen-Induced Arthritis in DBA/1 Mice,”Life Sciences63:8, 635-644 (1998).
Kruisselbrink, et al., “RecombinantLactobacillus plantaruminhibitis house dust mite-speicific T-Cell responses,”Clin. Exp. Imunol.126, 2-8 (2001).
Medaglini, et al., “Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacteriumStreptococcus gordoniiafter oral colonization,”Proc. Natl. Acad. Sci., 92, 6868-6872 (1995).
Moffatt, et al., “Naked DNA: New shots for allergy?,” Nature Medicine 2:5 (1996).
Cosgrove et al., “Group I allergens of grass pollen as cell wall loosening agents”,Proc. Natl. Acad. USA94:6559-6564 (1997).
Chew et al., “Allergenic differences between the domestic mitesBlomia tropicalisandDermatophagoides pteronyssinus”, Clin Exp Allergy29:982-988 (1999).
Fasler J. Allergy Clin Immunology 101(4):521-530, Apr. 1998.
Sato et al. Immunology 95(2):193-9, Oct. 1998.
Charng Yuh-Chyang
Hsu Ching-Hsiang
Genmont Biotechnology Co.
Li Q. Janice
LandOfFree
Live vaccines for allergy treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live vaccines for allergy treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live vaccines for allergy treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694962